I nflammatory bowel diseases (IBDs), comprising ulcerative colitis (UC) and Crohn's disease (CD), afflict an estimated 4 million people worldwide. 1 The chronic nature of these disorders, coupled with their increasing incidence and prevalence, has contributed to a significant IBD-related economic burden across the globe. 2, 3 The advent of anti-tumor necrosis factor (TNF) therapies in the late 1990s has revolutionized the treatment of IBD. [4] [5] [6] [7] [8] Over the past 2 decades, anti-TNF agents have become the mainstay of treatment of mild to moderate UC and CD. 9, 10 Although these agents have been shown to improve rates of mucosal healing compared with steroids, they also have been associated
with an increased risk of rare but potentially serious infections. 11 Of particular concern is reactivation of latent Mycobacterial tuberculosis (TB), which may present as disseminated infection. [12] [13] [14] As a result, current clinical guidelines recommend screening for latent TB before commencement of therapy with anti-TNF agents and deferring anti-TNF therapy until treatment for latent TB infection (LTBI) has been initiated. 13, [15] [16] [17] Although there is consensus on the need to screen patients for LTBI before initiating anti-TNF therapy, the choice of appropriate testing modality remains contentious. 18 The diagnosis of LTBI can be made with the tuberculin skin test or interferon-g release assay-based tests that measure sensitization to M tuberculosis by measuring interferon-g release in response to antigens representing M tuberculosis either from peripheral blood lymphocytes (T-SPOT.TB; Oxford Immunotec Limited, Abingdon, UK) or whole blood (QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube [QFT-GIT]; Cellestis Limited, Carnegie, Australia).
The tuberculin skin test (TST) was previously the favored tool to screen for LTBI; however, limitations include a high false-positive rate among patients who have received the Bacilli-Calmette-Guerin vaccine, a high false-negative rate among patients on immunosuppressive therapies, and the need for 2 visits before results are finalized. 19 The interferon-g release assay (IGRA) tests offer a less-cumbersome substitute and have been endorsed by the Centers for Disease Control as alternatives to the TST to screen for LTBI 20 ; they are preferred over TST for patients with a prior history of BacilliCalmette-Guerin vaccination or those unlikely to return to have their TST read (strong recommendation, moderate-quality evidence). 21 Among IBD patients, there is poor agreement between TST and QFT-GIT, with the former impacted negatively by immunosuppressive medications to a greater degree than the latter. 22 Hence, IBD patients are being screened increasingly for LTBI with IGRA-based tests, specifically the QFT-GIT assay. A significant proportion of these tests are reported as indeterminate; often triggering additional testing. Studies have shown a higher likelihood of indeterminate QFT-GIT results in patients with IBD and other chronic inflammatory conditions. 23 This may be owing in part to therapy for underlying disease because immunesuppressive medications can impact the yield of IGRA results negatively. 24 Specific to IBD, prior studies of factors influencing the yield of QFT-GIT have reported conflicting results. Although a study of 340 IBD patients did not identify any effect of immunosuppressive therapy or anti-TNF agents on QFT-GIT results, 25 other studies have observed a decrease in sensitivity for the QFT-GIT test in IBD patients who received immunosuppressive therapy. [26] [27] [28] These observations have been made in small cohorts that lacked distinction between corticosteroids and other immunomodulators (thiopurines and methotrexate) and anti-TNF agents in impacting QFT-GIT test results.
Because the diagnostic yield of QFT-GIT is based on antigen-triggered T-cell-mediated cytokine release, we hypothesized that corticosteroids, by suppressing T-cell function, may increase the likelihood of indeterminate QFT-GIT results independent of other immunemodulating medications or anti-TNF agents. Although this effect has been observed in autoimmune disorders, 23 the association specific to IBD has been limited to subgroup analyses of larger studies 29 and a single study of 45 IBD patients 30 ; neither of which accounted for disease activity. The aim of this study was to evaluate the effect of corticosteroids distinct from immune modulators, anti-TNF agents, and IBD disease activity on the likelihood of obtaining indeterminate QFT-GIT test results in a large cohort of IBD patients.
Methods

Study Population
The study cohort comprised IBD patients receiving care at a tertiary referral center who underwent QFT-GIT testing between January 2011 and May 2013. Patients with an established diagnosis of UC and CD based on clinical, endoscopic, radiographic, or histologic evidence were eligible for inclusion if they had undergone a QFT-GIT test to screen for LTBI before initiation of anti-TNF therapy or for surveillance for LTBI while on anti-TNF therapy. Patients with immune-suppressed states including human immunodeficiency virus infection or acquired immune deficiency syndrome, end-stage liver disease, chronic kidney disease, hematologic malignancies, poorly controlled diabetes, organ transplant recipients on chronic immune suppression, and patients undergoing cancer chemotherapy were excluded. Patients with incomplete data regarding diagnosis and concomitant medications also were excluded. The study was approved by the Institutional Review Board at Baylor College of Medicine.
Investigators (M.K., P.S., and N.K.) reviewed the medical records of eligible patients to extract data pertaining to demographics (age, sex, and race/ethnicity), body mass index, disease duration, diagnosis, and concomitant medications. Laboratory parameters including serum C-reactive protein (CRP), erythrocyte sedimentation rates (ESRs), serum albumin, and hemoglobin levels at the time of QFT testing were recorded.
QuantiFERON-Tuberculosis Gold In-Tube Interpretation Criteria
The QFT-GIT test measures cell-mediated immune responses to specific mycobacterial antigens (early secretory antigenic target-6, culture filtrate protein-10, and M tuberculosis antigen 7.7[p4]). Lymphocytes in the peripheral blood of individuals exposed to M tuberculosis secrete IFN-g upon contact with these antigens, forming the basis of this test. Whole blood is collected into 3 tubes: a Nil tube (negative control) without antigens or mitogens; a TB antigen tube, coated with mycobacterial antigens; and a mitogen tube coated with phytohemagglutinin, which activates T cells in an antigenindependent method and serves as a positive control. The amount of IFN-g in each tube is measured by enzyme-linked immunosorbent assay and reported in IU. The Nil sample adjusts for background IFN-g levels in blood and is subtracted from the levels in the TB antigen and Mitogen tubes. The test is reported as positive if the IFN-g levels in the TB antigen tube are significantly higher than the IFN-g levels in the Nil tube (0.35 IU/mL and 25% of Nil value). The test is reported as indeterminate when the IFN-g levels in the Mitogen tube are less than 0.5 IU/mL and the levels in the TB antigen tube are negative as well (<0.35 IU/mL or <25% of Nil value). 31 For this study, the mitogen response for each QFT-GIT test result was reviewed and results were confirmed as indeterminate if they met the criteria of low mitogen count (<0.5 IU/mL) and a negative response to TB antigens.
Statistical Analysis
We compared characteristics between IBD patients with indeterminate QFT-GIT test results and those with determinate (positive or negative) test results using the chi-square test for categoric variables and the Student t tests for continuous variables. We fitted multivariable logistic regression models to calculate the odds ratios (OR) and the 95% CIs for the association between the predictor variables and risk of having indeterminate QFT test results. Variables were included in the final multivariate model using a P value cut-off of .05 in the univariate analysis. The following variables were considered for inclusion: anti-TNF therapy, systemic corticosteroid use, serum albumin, hemoglobin, ESR, and CRP levels. All tests for statistical significance were 2-sided, with a P value less than .05 considered statistically significant. Statistical analyses were conducted using R statistics software (R Development Core Team, 2010, Vienna, Austria).
Results
There were 412 patients with IBD who underwent QFT-GIT testing from 2011 to 2013. Of these, 400 patients (265 CD and 135 UC) met eligibility criteria and were included in the final analyses. Characteristics of participants included in this analysis are presented in Table 1 . The mean age of the study participants was 40.4 years (SD, 14.8 y). The majority were female (56.7%) and Caucasian (62.5%). Two thirds of the study population had CD. None of the patients included in the study had a prior history of active TB or a previously positive result on the QFT-GIT test. Indeterminate results were noted in 46 (11.5%) cases. Among patients with determinate results, 2 were positive and 352 were negative.
Patients with indeterminate test results were more likely to be receiving systemic corticosteroids (P < .001), have lower albumin (P < .001) and hemoglobin levels (P ¼ .001), and higher serum ESR (P ¼ .01) and CRP levels (P ¼ .005) compared with patients with positive or negative test results (Table 2) . Age, sex, and race were not significantly different between indeterminate and determinate test groups. Harvey-Bradshaw disease activity indices of severity were available for 229 CD patients. Subgroup analyses did not identify any association between Harvey-Bradshaw disease activity index scores and QFT-GIT test results (P ¼ .67).
On multivariable analyses, systemic corticosteroid use (OR, 2.92; 95% CI, 1.44-5.88; P ¼ .003), and low albumin levels (<3.5 vs 3.5 g/dL; OR, 3.62; 95% CI, 1.36-9.60; P ¼ .009) were associated independently with an increased risk of indeterminate QFT-GIT test results (Table 3) . We did not identify a dose-related effect with corticosteroid use (Supplementary Table 1 ).
Discussion
In our study cohort of 400 IBD patients, systemic corticosteroid use and low albumin levels were associated with an increased likelihood of having an indeterminate QFT-GIT test result. Although we did not identify any association with immune-modulator therapy (P ¼ .87), ongoing treatment with anti-TNF agents decreased the odds of indeterminate QFT-GIT results. The negative impact of systemic corticosteroid use on the diagnostic yield of the QFT-GIT test, as observed in the study cohort, has been reported previously in patients with and without underlying IBD. 23, 29, 30, 32 The specific effect of corticosteroid use on mitogen-stimulated IFN-g release initially was observed in patients with active TB; this was attributed to the T-cell-suppressive effect of corticosteroids. 32 A similar association in IBD patients (without underlying TB infection) has been reported in 2 previous studies, both comprising relatively small cohorts. 29, 30 The larger study had a subgroup of 73 IBD patients (19 UC and 54 CD), none of whom were on anti-TNF therapy. Among these patients, oral prednisolone, but not long-acting injectable corticosteroid therapy, was associated with indeterminate QFT results (P < .001). 29 The second study comprised 45 IBD patients, indeterminate QFT results were observed in 13 (28.9%) patients and were associated with corticosteroid doses of greater than 15 mg/d (P ¼ .002). 30 We did not identify a similar dose-related effect of corticosteroids in our study.
In addition to systemic corticosteroids, we identified low albumin levels as associated independently with an increased risk of indeterminate QuantiFERON-TB Gold results. Patients with albumin levels less than 3.5 g/dL had an almost 75% higher odds of indeterminate QFT-GIT results compared with those with albumin levels in the normal range (3.5-5 g/dL). A similar association between hypoalbuminemia and indeterminate QFT-GIT test results has been reported previously in hospitalized patients without a diagnosis of IBD. 33 Among patients with IBD, a related observation was made in a study of 72 pediatric IBD patients (59 CD and 14 UC) by Hradsky et al, 34 who reported lower levels of albumin in patients with indeterminate QFT results; however, the association did not remain significant on multivariable analyses. The current study reports an association between low albumin levels and an increased likelihood of indeterminate QFT-GIT results in adult IBD patients.
In addition to lower serum albumin levels, patients with indeterminate QFT-GIT results in our study had higher levels of serum ESR and CRP. Because hypoalbuminemia can be the result of malnutrition and inflammation, the latter owing to a greater fractional catabolic rate and increased transfer of albumin in to Reference range for hemoglobin levels was 11.5 to 15.5 g/dL for women and 13 to 17 g/dL for men. Reference range for hemoglobin levels was 11.5 to 15.5 g/dL for females and 13 to 17 g/dL for males.
the extravascular compartment, 35 it is likely that the observed association with hypoalbuminemia reflects the influence of systemic inflammatory burden related to disease activity on QFT-GIT results, as has been reported previously in immune-mediated disorders, including IBD. 34, 35 Additional factors such as extremes of age, iron-deficiency anemia, and female sex have been associated previously with indeterminate QFT-GIT results in patients with and without underlying immune-mediated disorders. 36, 37 Although patients with indeterminate results in our study had lower hemoglobin levels, this association did not remain significant on multivariable analyses. We did not identify any variations with age or sex in QFT-GIT test results. Although a previous study of pediatric patients identified disease activity (assessed by the Pediatric Crohn's Disease Activity Index) as an independent risk factor for indeterminate IGRA results, we did not identify an association between clinical disease activity indices for CD patients in the study cohort and QFT-GIT results. 34 In our study, patients with indeterminate QFT-GIT tests underwent repeat testing as well as chest radiographs. On repeat testing, 38 of 46 patients had indeterminate results and the rest were negative. None of the patients who underwent chest radiographs had any abnormal findings. Nine patients were initiated on empiric treatment for latent TB, despite indeterminate test results, because of a history of potential exposure to TB. There were no cases of active TB infection. In our study, patients with indeterminate QFT results had an average lag of approximately 3 weeks (range, 2-7 wk) from initial QFT-GIT results to initiating anti-TNF therapy. Based on these data, it is evident that the risk of active TB is very low in this population. Because additional testing almost always further delays anti-TNF therapy while simultaneously prolonging the duration of corticosteroid exposure for most patients, our observation highlights the need to limit additional testing (such as repeat QFT-GIT, TST, or sputum cultures) to patients with abnormal findings on chest radiographs or known risk factors for LTBI to avoid unnecessary delay in initiating steroid-sparing therapy with anti-TNF agents.
Our study had several limitations. The retrospective nature of the study limited our ability to establish causation. It would be beneficial to confirm our findings in a prospective study. In addition, the patient cohort for our study was drawn from a single tertiary referral center and may not be reflective of the IBD patient population at large. We attempted to mitigate this effect by including medication history and objective markers of disease severity in the analysis.
The strengths of the study included the cohort size, it was a large cohort of IBD patients with QFT-GIT test results. Unlike prior studies, we were able to extract detailed information pertaining to concomitant medications. This allowed for studying the effects of corticosteroids, independent of anti-TNF agents and other immune-modulating drugs. Finally, we included objective markers of inflammation to account for the influence of disease activity on QFT-GIT results along with clinical indices of disease activity for CD patients.
In summary, we have identified systemic corticosteroid use and low albumin levels as possible contributors to indeterminate QFT-GIT results in a large cohort of IBD patients. Because indeterminate QFT-GIT test results frequently trigger additional testing and delay in initiation of anti-TNF therapy, the results of this study suggest it may be advantageous to screen IBD patients for latent TB before initiation of systemic corticosteroids. Among patients already on corticosteroids, an indeterminate QFT-GIT result is of limited diagnostic utility and it may be beneficial to obtain a chest radiograph. In areas with low rates of TB infection, additional testing or treatment for LTBI then can be limited to patients with known risk factors and abnormalities on chest radiograph, thereby avoiding unwarranted delay in initiating anti-TNF therapy for patients lacking risk factors for LTBI.
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